{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981859",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981859_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"acarbose\" outputclass=\"int-drug\">acarbose</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  acarbose  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acarbose</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981860",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981860_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">Apalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Apalutamide   is predicted to   decrease   the exposure to   linagliptin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981861",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981861_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"canagliflozin\" outputclass=\"int-drug\">canagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  canagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Canagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981862",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981862_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decrease   the exposure to   linagliptin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981863",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981863_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"dapagliflozin\" outputclass=\"int-drug\">dapagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  dapagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981864",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981864_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"dulaglutide\" outputclass=\"int-drug\">dulaglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  dulaglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dulaglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981865",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981865_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"empagliflozin\" outputclass=\"int-drug\">empagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  empagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Empagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981866",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981866_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"enzalutamide\" outputclass=\"int-drug\">Enzalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Enzalutamide   is predicted to   decrease   the exposure to   linagliptin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enzalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981867",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981867_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"ertugliflozin\" outputclass=\"int-drug\">ertugliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  ertugliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ertugliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981868",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981868_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"exenatide\" outputclass=\"int-drug\">exenatide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  exenatide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Exenatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981869",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981869_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fenfluramine\" outputclass=\"int-drug\">Fenfluramine</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">blood glucose concentrations when given with</ph> <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fenfluramine   might   decrease   blood glucose concentrations when given with   linagliptin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fenfluramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981870",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981870_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   decrease   the exposure to   linagliptin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981871",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981871_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"glibenclamide\" outputclass=\"int-drug\">glibenclamide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  glibenclamide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glibenclamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981872",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981872_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"gliclazide\" outputclass=\"int-drug\">gliclazide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  gliclazide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gliclazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981873",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981873_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"glimepiride\" outputclass=\"int-drug\">glimepiride</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  glimepiride  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glimepiride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981874",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981874_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"glipizide\" outputclass=\"int-drug\">glipizide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  glipizide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glipizide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981875",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981875_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"insulin\" outputclass=\"int-drug\">insulin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  insulin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Insulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981876",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981876_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"liraglutide\" outputclass=\"int-drug\">liraglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  liraglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Liraglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981877",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981877_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"lixisenatide\" outputclass=\"int-drug\">lixisenatide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  lixisenatide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lixisenatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981878",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981878_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">Linagliptin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"lomitapide\" outputclass=\"int-drug\">lomitapide</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 12 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Linagliptin   is predicted to   increase   the exposure to   lomitapide .  Manufacturer advises separate administration by 12 hours .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lomitapide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981879",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981879_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"metformin\" outputclass=\"int-drug\">metformin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  metformin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metformin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981880",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981880_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"mitotane\" outputclass=\"int-drug\">Mitotane</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Mitotane   is predicted to   decrease   the exposure to   linagliptin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981881",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981881_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decrease   the exposure to   linagliptin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981882",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981882_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   decrease   the exposure to   linagliptin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981883",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981883_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"pioglitazone\" outputclass=\"int-drug\">pioglitazone</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  pioglitazone  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pioglitazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981884",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981884_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decrease   the exposure to   linagliptin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981885",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981885_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"repaglinide\" outputclass=\"int-drug\">repaglinide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  repaglinide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Repaglinide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981886",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981886_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the exposure to   linagliptin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981887",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981887_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"semaglutide\" outputclass=\"int-drug\">semaglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  semaglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Semaglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981888",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2#bnf_i1643857981888_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"linagliptin\" outputclass=\"int-heading-drug\">linagliptin</ph> and <ph otherprops=\"tolbutamide\" outputclass=\"int-drug\">tolbutamide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  linagliptin  and  tolbutamide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolbutamide</title>"
					}
				}
			],
			"hasSearchLabel": " Linagliptin  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/linagliptin-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Linagliptin </title>"
			},
			"rdfs:label": "linagliptin"
		}
	]
}